---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-052579"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2024-12-30T23:59:59+00:00"
generated_at: "2026-05-28T22:36:47.699460+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Pfizer terminates hemophilia A gene therapy deal with Sangamo; milestone payments lost

## Summary
- Pfizer notified Sangamo of termination for convenience effective April 21, 2025; no BLA or MAA to be submitted.
- Sangamo forfeits up to $220M in remaining milestones and all future royalties (14-20% of net sales).
- Sangamo receives exclusive license back to develop and commercialize SB-525; Pfizer gets low single digit royalties.
- Sangamo plans to seek a new partner to advance regulatory filings for giroctocogene fitelparvovec.
- Pfizer had paid $125M already ($70M upfront + $55M milestones); remaining program rights revert.

## SEC filing metadata
- accession: 0001628280-24-052579
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2024-12-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828024052579/0001628280-24-052579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828024052579/sgmo-20241222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-052579
- JSON: https://secwatch.observer/filing/0001628280-24-052579.json
- Plain text: https://secwatch.observer/filing/0001628280-24-052579.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.